Drug Intensification in Future Postoperative Radiotherapy Practice in Biochemically-Relapsing Prostate Cancer Patients.

Abstract

Although salvage prostate bed radiotherapy is highly effective in biochemically-relapsing prostate cancer patients following prostatectomy, relapses remain frequent and improvements are needed. Randomized phase 3 trials have shown the benefit of adding androgen-depriving therapy to irradiation, but not all patients benefit from this combination. Preclinical studies have shown that novel agents targeting the androgen receptor, DNA repair, PI3K/AKT/mTOR pathways, or the hypoxic microenvironment may help increase the response to prostate bed irradiation while minimizing potential side effects. This perspective review focuses on the most relevant molecules that may have an impact when combined with salvage radiotherapy, and underlines the strategies that need to be developed to increase the efficacy of salvage post-prostatectomy radiotherapy in prostate cancer patients.

• Authors: Axel Cailleteau, Paul Sargos, Fred Saad, Igor Latorzeff, Stéphane Supiot
• Journal: Frontiers in oncology (Front Oncol) Vol. 11 Pg. 780507 ( 2021) ISSN: 2234-943X [Print] Switzerland
• PMID: 35004302 (Publication Type: Journal Article)
• Copyright: Copyright © 2021 Cailleteau, Sargos, Saad, Latorzeff and Supiot.